KIFC1 regulates ZWINT to promote tumor progression and spheroid formation in colorectal cancer.


Journal

Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 12 01 2021
accepted: 12 03 2021
pubmed: 6 4 2021
medline: 19 1 2022
entrez: 5 4 2021
Statut: ppublish

Résumé

Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide. Kinesin Family Member C1 (KIFC1) has been proposed as a promising therapeutic target due to its pivotal role in centrosome clustering to mediate cancer cell progression. This study aimed to analyze the expression and biological function of KIFC1 in CRC. Immunohistochemically, 67 (52%) of 129 CRC cases were positive for KIFC1 and statistically associated with poorer overall survival. KIFC1 small interfering RNA (siRNA)-transfected cells demonstrated lower cell proliferation as compared to the negative control cells. A specific KIFC1 inhibitor, kolavenic acid analog (KAA) drastically inhibited CRC cell proliferation. Microarray analysis revealed that KAA-treated CRC cells presented reduced ZW10 interacting kinetochore protein (ZWINT) expression as compared to control cells. Immunohistochemical analysis demonstrated that 61 (47%) of 129 CRC cases were positive for ZWINT and ZWINT expression was significantly correlated with KIFC1 expression. ZWINT-positive cases exhibited significantly worse overall survival. KIFC1 siRNA-transfected cells showed reduced ZWINT expression while ZWINT siRNA-transfected cells decreased cell proliferation. Both KIFC1 and ZWINT knockdown cells attenuated spheroid formation ability. This study provides new insights into KIFC1 regulating ZWINT in CRC progression and its potential as a therapeutic target.

Identifiants

pubmed: 33819373
doi: 10.1111/pin.13098
doi:

Substances chimiques

Antineoplastic Agents 0
Biomarkers, Tumor 0
Diterpenes 0
Intracellular Signaling Peptides and Proteins 0
KIFC1 protein, human 0
Nuclear Proteins 0
RNA, Small Interfering 0
ZWINT protein, human 0
kolavenol 0
Kinesins EC 3.6.4.4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

441-452

Subventions

Organisme : Takeda Science Foundation
Organisme : Japan Society for the Promotion of Science

Informations de copyright

© 2021 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Références

Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
Favoriti P , Carbone G , Greco M , Pirozzi F , Pirozzi REM , Corcione F. Worldwide burden of colorectal cancer: A review. Updates Surg 2016; 68: 7-11.
DeSantis CE , Lin CC , Mariotto AB et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64: 252-71.
Bessède E , Dubus P , Mégraud F , Varon C. Helicobacter pylori infection and stem cells at the origin of gastric cancer. Oncogene 2015; 34: 2547-55.
Wakamatsu Y , Sakamoto N , Oo HZ et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int 2012; 62: 112-19.
Takaishi S , Okumura T , Wang TC. Gastric cancer stem cells. J Clin Oncol 2008; 26: 2876-82.
Oue N , Mukai S , Imai T et al. Induction of KIFC1 expression in gastric cancer spheroids. Oncol Rep 2016; 36: 349-55.
Liu X , Gong H , Huang K. Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Sci 2013; 104: 651-56.
Pannu V , Rida PCG , Ogden A et al. HSET overexpression fuels tumor progression via centrosome clustering-independent mechanisms in breast cancer patients. Oncotarget 2015; 6: 6076-91.
Han J , Wang F , Lan Y et al. KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling. Oncogene 2019; 38: 406-20.
Li G , Chong T , Yang J , Li H , Chen H. Kinesin motor protein KIFC1 is a target protein of mir-338-3p and is associated with poor prognosis and progression of renal cell carcinoma. Oncol Res 2018; 27: 125-37.
Cosenza MR , Krämer A. Centrosome amplification, chromosomal instability and cancer: Mechanistic, clinical and therapeutic issues. Chromosome Res 2016; 24: 105-26.
Imai T , Oue N , Yamamoto Y et al. Overexpression of KIFC1 and its association with spheroid formation in esophageal squamous cell carcinoma. Pathol Res Pract 2017; 213: 1388-93.
Sekino Y , Oue N , Shigematsu Y et al. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer. Urol Oncol Semin Orig Investig 2017; 35: 31.e13-31.e20.
Yukawa M , Yamauchi T , Kurisawa N , Ahmed S , Kimura K , Toda T. Fission yeast cells overproducing HSET/KIFC1 provides a useful tool for identification and evaluation of human kinesin-14 inhibitors. Fungal Genet Biol 2018; 116: 33-41.
Kurisawa N , Yukawa M , Koshino H , Onodera T , Toda T , Kimura K. Kolavenic acid analog restores growth in HSET-overproducing fission yeast cells and multipolar mitosis in MDA-MB-231 human cells. Bioorganic Med Chem 2020; 28: 115154.
Ying H , Xu Z , Chen M , Zhou S , Liang X , Cai X. Overexpression of Zwint predicts poor prognosis and promotes the proliferation of hepatocellular carcinoma by regulating cell-cycle-related proteins. Onco Targets Ther 2018; 11: 689-702.
Sakamoto N , Oue N , Sentani K et al. Liver-intestine cadherin induction by epidermal growth factor receptor is associated with intestinal differentiation of gastric cancer. Cancer Sci 2012; 103: 1744-50.
Fujita T , Chiwaki F , Takahashi R et al. Identification and characterization of CXCR4-positive gastric cancer stem cells. PLoS One 2015; 10: 1-19.
Li S , Schmitz KR , Jeffrey PD , Wiltzius JJW , Kussie P , Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-11.
Fang JYRB. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005; 6: 322-27.
Cimino SK , Eng C. Up-and-coming experimental drug options for metastatic colorectal cancer. J Exp Pharmacol 2020; 12: 475-85.
Grothey A , Sobrero AF , Shields AF et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018; 378: 1177-88.
Kim N , Song K. KIFC1 is essential for bipolar spindle formation and genomic stability in the primary human fibroblast IMR-90 cell. Cell Struct Funct 2013; 38: 21-30.
Xiao Y-X , Yang W-X. KIFC1: A promising chemotherapy target for cancer treatment? Oncotarget 2016; 7: 48656-70.
Wang H , Hu X , Ding X et al. Human Zwint-1 specifies localization of Zeste White 10 to kinetochores and is essential for mitotic checkpoint signaling. J Biol Chem 2004; 279: 54590-98.
Lin YT , Chen Y , Wu G , Lee WH. Hec1 sequentially recruits Zwint-1 and ZW10 to kinetochores for faithful chromosome segregation and spindle checkpoint control. Oncogene 2006; 25: 6901-14.
Yuan W , Xie S , Wang M et al. Bioinformatic analysis of prognostic value of ZW10 interacting protein in lung cancer. Onco Targets Ther 2018; 11: 1683-95.
Todaro M , Francipane MG , Medema JP , Stassi G. Colon cancer stem cells: Promise of targeted therapy. Gastroenterology 2010; 138: 2151-62.
Clarke MF , Al-Hajj M , Morrison SJ , Wicha MS , Benito-Hernandez A. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-88.
Pan S , Zhan Y , Chen X , Wu B , Liu B. Identification of biomarkers for controlling cancer stem cell characteristics in bladder cancer by network analysis of transcriptome data stemness indices. Front Oncol 2019; 9: 1-11.
Liu D , Xu X , Wen J et al. Integrated genome-wide analysis of gene expression and DNA copy number variations highlights stem cell-related pathways in small cell esophageal carcinoma. Stem Cells Int 2018; 2018: 1-9.

Auteurs

Shintaro Akabane (S)

Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Naohide Oue (N)

Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Yohei Sekino (Y)

Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Ryuichi Asai (R)

Department of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan.

Pham Quoc Thang (PQ)

Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Daiki Taniyama (D)

Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Kazuhiro Sentani (K)

Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Masashi Yukawa (M)

Hiroshima Research Center for Healthy Aging, Department of Molecular Biotechnology, Graduate School of Integrated Sciences for Life, Hiroshima University, Hiroshima, Japan.

Takashi Toda (T)

Hiroshima Research Center for Healthy Aging, Department of Molecular Biotechnology, Graduate School of Integrated Sciences for Life, Hiroshima University, Hiroshima, Japan.

Ken-Ichi Kimura (KI)

Chemical Biology Laboratory, Graduate School of Arts and Sciences, Iwate University, Iwate, Japan.

Hiroyuki Egi (H)

Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Wataru Shimizu (W)

Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Hideki Ohdan (H)

Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Wataru Yasui (W)

Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH